Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 8/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 8/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30240763 | 0.86 | HSD17B1 (0.37) | HSD17B2HSD17B1SCN9AFFAR4CAMKK2 | |
| SCHEMBL24933610 | 0.86 | HSD17B1 (0.37) | HSD17B2HSD17B1SCN9AFFAR4CAMKK2 | |
| SCHEMBL30240751 | 0.86 | HSD17B1 (0.41) | HSD17B2HSD17B1SCN9ACDK5CDK5R1 | |
| SCHEMBL24933735 | 0.86 | HSD17B1 (0.41) | HSD17B2HSD17B1SCN9ACDK5CDK5R1 | |
| SCHEMBL24933386 | 0.85 | CDC7 (0.38) | HSD17B2HSD17B1CYP11B2CDK5CDK5R1 | |
| SCHEMBL30240731 | 0.84 | PARP10 (0.41) | HSD17B2HSD17B1CDK5CDK5R1 | |
| SCHEMBL24933028 | 0.84 | PARP10 (0.41) | HSD17B2HSD17B1CDK5CDK5R1 | |
| SCHEMBL30240778 | 0.84 | MKNK1 (0.43) | HSD17B2HSD17B1CYP11B2CDK5CDK5R1 | |
| SCHEMBL24933882 | 0.84 | MKNK1 (0.43) | HSD17B2HSD17B1CYP11B2CDK5CDK5R1 | |
| SCHEMBL24933810 | 0.83 | FFAR4 (0.40) | HSD17B2HSD17B1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |